Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

View more from the 2013 ASCO Annual Meeting

Videos

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer. 

Andreas du Bois, MD

Articles

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer